Last quarter (Q4 2023), Y-Mabs Therapeutics's total revenue was $23.36M, an increase of Infinity% from the same quarter last year. In Q4, Y-Mabs Therapeutics's net income was $-988.00K. See Y-Mabs Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 84.82M	$ 84.82M	$ 65.27M	$ 34.90M	$ 20.75M	$ 0.00
Cost of Revenue	$ 11.37M	$ 11.37M	$ 7.47M	$ -2.30M	$ 2.20M	$ 0.00
Gross Profit	$ 73.45M	$ 73.45M	$ 57.80M	$ 32.38M	$ 18.55M	$ 0.00
Operating Expense	$ 99.08M	$ 99.08M	$ 152.51M	$ 147.82M	$ 138.48M	$ 83.00M
Operating Income	$ -25.67M	$ -25.67M	$ -94.81M	$ -115.43M	$ -119.94M	$ -83.00M
Net Non Operating Interest Income Expense	-	-	-	-	$ 598.00K	$ 1.98M
Other Income Expense	-	-	$ 757.00K	$ -60.16M	$ -2.20M	-
Pretax Income	$ -20.87M	$ -20.87M	$ -95.37M	$ -55.27M	$ -119.34M	$ -81.03M
Tax Provision	$ 561.00K	$ 561.00K	$ -5.66M	$ -304.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -21.52M	$ -21.43M	$ -95.37M	$ -55.27M	$ -119.34M	$ -81.03M
Basic EPS	$ -0.49	$ -0.49	$ -2.19	$ -1.28	$ -2.97	$ -2.30
Diluted EPS	$ -0.49	$ -0.49	$ -2.19	$ -1.28	$ -2.97	$ -2.30
Basic Average Shares	$ 174.58M	$ 43.65M	$ 43.70M	$ 43.18M	$ 40.12M	$ 35.18M
Diluted Average Shares	$ 174.58M	$ 43.65M	$ 43.70M	$ 43.18M	$ 40.12M	$ 35.18M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 110.44M	$ 110.44M	$ 159.98M	$ 145.51M	$ 140.69M	$ 83.00M
Net Income From Continuing And Discontinued Operation	$ -21.43M	$ -21.43M	$ -95.57M	$ -55.27M	$ -119.34M	$ -81.03M
Normalized Income	$ -11.44M	$ -12.00M	$ -100.41M	-	$ -119.34M	$ -81.03M
Interest Expense	-	-	-	-	-	-
EBIT	$ -20.87M	$ -20.87M	$ -95.37M	$ -55.27M	$ -119.94M	$ -83.00M
EBITDA	$ -12.74M	$ -20.13M	$ -94.53M	$ -55.92M	$ -119.54M	$ -82.84M

Currency in USD

Y-Mabs Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing